钴衍生物作为有前途的治疗剂。
Cobalt derivatives as promising therapeutic agents.
机构信息
Department of Chemistry, Molecular Biosciences, Neurobiology, Biomedical Engineering, and Radiology, Northwestern University, Evanston, IL 60208-3113, United States.
出版信息
Curr Opin Chem Biol. 2013 Apr;17(2):189-96. doi: 10.1016/j.cbpa.2012.11.019. Epub 2012 Dec 24.
Abstract
Inorganic complexes are versatile platforms for the development of potent and selective pharmaceutical agents. Cobalt possesses a diverse array of properties that can be manipulated to yield promising drug candidates. Investigations into the mechanism of cobalt therapeutic agents can provide valuable insight into the physicochemical properties that can be harnessed for drug development. This review presents examples of bioactive cobalt complexes with special attention to their mechanisms of action. Specifically, cobalt complexes that elicit biological effects through protein inhibition, modification of drug activity, and bioreductive activation are discussed. Insights gained from these examples reveal features of cobalt that can be rationally tuned to produce therapeutics with high specificity and improved efficacy for the biomolecule or pathway of interest.
摘要
无机配合物是开发高效和选择性药物的多功能平台。钴具有多种性质，可以通过操纵这些性质来产生有前途的药物候选物。对钴治疗剂的作用机制的研究可以为药物开发提供有价值的见解，了解可以利用哪些物理化学性质。本综述介绍了具有生物活性的钴配合物的实例，特别关注它们的作用机制。具体来说，讨论了通过蛋白质抑制、药物活性修饰和生物还原激活来产生生物学效应的钴配合物。从这些例子中获得的见解揭示了钴的一些特征，可以对其进行合理调整，从而产生针对感兴趣的生物分子或途径的具有高特异性和改善疗效的治疗剂。
相似文献
1
Cobalt derivatives as promising therapeutic agents.钴衍生物作为有前途的治疗剂。
Curr Opin Chem Biol. 2013 Apr;17(2):189-96. doi: 10.1016/j.cbpa.2012.11.019. Epub 2012 Dec 24.
2
Advances in cobalt complexes as anticancer agents.钴配合物作为抗癌剂的研究进展。
Dalton Trans. 2015 Aug 21;44(31):13796-808. doi: 10.1039/c5dt02101d.
3
Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.提高 EGFR 抑制剂钴(III)前药的稳定性。
Inorg Chem. 2020 Dec 7;59(23):17794-17810. doi: 10.1021/acs.inorgchem.0c03083. Epub 2020 Nov 21.
4
Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.发现一种钴(III)席夫碱配合物，能诱导伯基特样淋巴瘤和白血病细胞凋亡，克服体外多药耐药。
Bioorg Chem. 2020 Nov;104:104193. doi: 10.1016/j.bioorg.2020.104193. Epub 2020 Sep 1.
5
Synthesis, Characterization, and Cytotoxicity of the Cobalt (III) Complex with N,N-Diethyl-4-(2,2':6',2''-terpyridin-4'-yl)aniline.含N,N-二乙基-4-(2,2':6',2''-三联吡啶-4'-基)苯胺的钴(III)配合物的合成、表征及细胞毒性
Chem Biodivers. 2018 Oct;15(10):e1800215. doi: 10.1002/cbdv.201800215. Epub 2018 Sep 21.
6
Antiproliferative, DNA binding, and cleavage properties of dinuclear Co(III) complexes containing the bioactive quinizarin ligand.含生物活性喹哪啶配体的双核 Co(III) 配合物的抗增殖、DNA 结合和断裂特性。
J Biol Inorg Chem. 2020 Mar;25(2):339-350. doi: 10.1007/s00775-020-01765-4. Epub 2020 Feb 28.
7
Cobalt amine complexes and Ru265 interact with the DIME region of the mitochondrial calcium uniporter.钴胺配合物和 Ru265 与线粒体钙单向转运蛋白的 DIME 区域相互作用。
Chem Commun (Camb). 2021 Jun 22;57(50):6161-6164. doi: 10.1039/d1cc01623g.
8
New Cobalt (II) Complexes with Imidazole Derivatives: Antimicrobial Efficiency against Planktonic and Adherent Microbes and In Vitro Cytotoxicity Features.新型钴（II）配合物与咪唑衍生物：对浮游和黏附微生物的抗菌效率和体外细胞毒性特征。
Molecules. 2020 Dec 24;26(1):55. doi: 10.3390/molecules26010055.
9
Mixed-Ligand Cobalt(III) Complexes of a Naturally Occurring Coumarin and Phenanthroline Bases as Mitochondria-Targeted Dual-Purpose Photochemotherapeutics.天然香豆素和菲咯啉碱基的混合配体钴(III)配合物作为线粒体靶向双重用途光化疗药物。
Inorg Chem. 2021 May 3;60(9):6649-6662. doi: 10.1021/acs.inorgchem.1c00444. Epub 2021 Apr 15.
10
Evaluation of cobalt(III) complexes as potential hypoxia-responsive carriers of esculetin.钴（III）配合物作为七叶亭潜在的缺氧响应载体的评估。
J Inorg Biochem. 2020 Oct;211:111211. doi: 10.1016/j.jinorgbio.2020.111211. Epub 2020 Aug 8.
引用本文的文献
1
A glimpse into the developments, potential leads and future perspectives of anticancer cobalt complexes.抗癌钴配合物的发展、潜在线索及未来展望一瞥。
RSC Med Chem. 2025 Jun 24. doi: 10.1039/d5md00323g.
2
Cobalt(II) Complexes of 4'-Nitro-Fenamic Acid: Characterization and Biological Evaluation.4'-硝基芬那酸的钴（II）配合物：表征与生物学评价
Molecules. 2025 Jun 17;30(12):2621. doi: 10.3390/molecules30122621.
3
Piperazine-Based Co(III), Ni(II), Cu(II), and Zn(II) Carbodithioate Complexes as Potential Anticancer Agent.基于哌嗪的二硫代碳酸钴（III）、镍（II）、铜（II）和锌（II）配合物作为潜在抗癌剂
ACS Omega. 2025 Apr 1;10(14):13829-13838. doi: 10.1021/acsomega.4c06972. eCollection 2025 Apr 15.
4
Gli pathway-targeted Co(iii) Schiff base complexes inhibit migration of basal cell carcinoma cells.Gli信号通路靶向的钴（III）席夫碱配合物抑制基底细胞癌细胞的迁移。
RSC Adv. 2025 Mar 19;15(11):8572-8579. doi: 10.1039/d5ra00326a. eCollection 2025 Mar 17.
5
Importance of trace elements in the immunometabolic health of people living with HIV/AIDS: a literature review.微量元素在人类免疫缺陷病毒/获得性免疫缺陷综合征（HIV/AIDS）感染者免疫代谢健康中的重要性：一项文献综述
Mol Biol Rep. 2024 Dec 21;52(1):71. doi: 10.1007/s11033-024-10186-4.
6
Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals.控制钴放射性药物的氧化还原化学
Angew Chem Int Ed Engl. 2024 Dec 9;63(50):e202412357. doi: 10.1002/anie.202412357. Epub 2024 Nov 5.
7
Cobalt(III)-Macrocyclic Scaffolds with Anti-Cancer Stem Cell Activity.具有抗癌干细胞活性的钴(III)-大环支架。
Molecules. 2024 Jun 8;29(12):2743. doi: 10.3390/molecules29122743.
8
Small-Molecule Fluorescent Probes for Binding- and Activity-Based Sensing of Redox-Active Biological Metals.用于基于结合和活性的氧化还原活性生物金属的小分子荧光探针。
Chem Rev. 2024 May 8;124(9):5846-5929. doi: 10.1021/acs.chemrev.3c00819. Epub 2024 Apr 24.
9
Cobalt complexes modulate plasmid conjugation in Escherichia coli and Klebsiella pneumoniae.钴配合物调节大肠杆菌和肺炎克雷伯菌中的质粒接合。
Sci Rep. 2024 Apr 6;14(1):8103. doi: 10.1038/s41598-024-58895-x.
10
Exploiting Co(III)-Cyclopentadienyl Complexes To Develop Anticancer Agents.利用 Co(III)-环戊二烯基配合物开发抗癌剂。
Inorg Chem. 2024 Apr 1;63(13):5783-5804. doi: 10.1021/acs.inorgchem.3c03696. Epub 2024 Mar 19.
本文引用的文献
1
Cobalt Complexes as Antiviral and Antibacterial Agents.钴配合物作为抗病毒和抗菌剂
Pharmaceuticals (Basel). 2010 May 26;3(6):1711-1728. doi: 10.3390/ph3061711.
2
Kinetics and thermodynamics of irreversible inhibition of matrix metalloproteinase 2 by a Co(III) Schiff base complex.基质金属蛋白酶 2 不可逆抑制的动力学和热力学：钴（III）希夫碱配合物的作用。
J Biol Inorg Chem. 2012 Aug;17(6):853-60. doi: 10.1007/s00775-012-0902-3. Epub 2012 May 22.
3
DNA-binding small molecules as inhibitors of transcription factors.DNA 结合小分子作为转录因子抑制剂。
Med Res Rev. 2013 Jul;33(4):823-46. doi: 10.1002/med.21266. Epub 2012 Apr 30.
4
Targeted inactivation of Snail family EMT regulatory factors by a Co(III)-Ebox conjugate.通过 Co(III)-Ebox 缀合物靶向失活 Snail 家族 EMT 调节因子。
PLoS One. 2012;7(2):e32318. doi: 10.1371/journal.pone.0032318. Epub 2012 Feb 29.
5
Redox activation of metal-based prodrugs as a strategy for drug delivery.基于氧化还原的金属前药激活策略用于药物递送。
Adv Drug Deliv Rev. 2012 Aug;64(11):993-1004. doi: 10.1016/j.addr.2012.01.007. Epub 2012 Jan 25.
6
Specific inhibition of the transcription factor Ci by a cobalt(III) Schiff base-DNA conjugate.钴(III)席夫碱-DNA 缀合物特异性抑制转录因子 Ci。
Mol Pharm. 2012 Feb 6;9(2):325-33. doi: 10.1021/mp2005577. Epub 2012 Jan 20.
7
Cobalt(II) complexes with non-steroidal anti-inflammatory drug tolfenamic acid: Structure and biological evaluation.钴(II)配合物与非甾体抗炎药托芬那酸的结构和生物评价。
Eur J Med Chem. 2012 Feb;48:132-42. doi: 10.1016/j.ejmech.2011.12.004. Epub 2011 Dec 9.
8
Biological evaluation of cobalt(II) complexes with non-steroidal anti-inflammatory drug naproxen.非甾体类抗炎药萘普生与钴(II)配合物的生物学评价。
J Inorg Biochem. 2012 Feb;107(1):54-64. doi: 10.1016/j.jinorgbio.2011.10.014. Epub 2011 Nov 3.
9
Effects of tethered ligands and of metal oxidation state on the interactions of cobalt complexes with the 26S proteasome.配体束缚效应对钴配合物与 26S 蛋白酶体相互作用的影响及其金属氧化态的影响。
J Inorg Biochem. 2011 Dec;105(12):1759-66. doi: 10.1016/j.jinorgbio.2011.09.013. Epub 2011 Sep 16.
10
17 e- rhenium dicarbonyl CO-releasing molecules on a cobalamin scaffold for biological application.基于钴胺素支架的 17 个电子铼二羰基 CO 释放分子用于生物应用。
Dalton Trans. 2012 Jan 14;41(2):370-8. doi: 10.1039/c1dt10649j. Epub 2011 Sep 1.
Zotero 插件